VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALEC
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALECAlector, Inc.
$2.56$284M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksALECFinancials

Alector, Inc. (ALEC) Income Statement

10Y historyFree accessUpdated daily

Quarterly revenue has collapsed 94% from $54.2M in 2024Q4 to $3.3M in 2026Q2 with erratic gross margins swinging between -99.2% and 100%, while operating losses persist at -$24.4M despite R&D cuts of 64%.

Income StatementBalance SheetCash FlowRatios

ALEC Income Statement

Annual statement

ALEC Income Statement

Alector, Inc. (ALEC) annual income statement — 10-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16
Sales/Revenue173.47M21.05M100.56M97.06M133.62M207.09M21.1M21.22M27.68M3.73M416K
Revenue Growth %151.23%-79.07%3.6%-27.36%-35.48%881.54%-0.57%-23.33%641.02%797.84%-
Cost of Goods Sold09.66M185.94M8.85M0189.41M156.87M100.53M73.03M29.91M13.67M
COGS % of Revenue-45.91%184.91%9.12%-91.46%743.53%473.76%263.87%800.83%3287.02%
Gross Profit10.6M11.38M-85.38M88.21M133.62M17.68M-135.77M-79.31M-45.35M-26.18M-13.26M
Gross Margin %6.11%54.09%-84.91%90.88%100%8.54%-643.53%-373.76%-163.87%-700.83%-3187.02%
Gross Profit Growth %-113.33%-196.79%-33.98%655.84%113.02%-71.19%-74.87%-73.27%-97.44%-
Operating Expenses138.51M157.19M59.62M239.95M271.45M55.04M59.4M35.09M84.97M36.41M15.55M
OpEx % of Revenue-746.93%59.28%247.22%203.16%26.58%281.56%165.39%306.99%974.94%3737.5%
Selling, General & Admin38.69M53.99M57.41M56.69M61.03M55.04M59.4M33.94M11.93M6.5M1.87M
SG&A % of Revenue-256.53%57.09%58.4%45.68%26.58%281.56%159.94%43.12%174.11%450.48%
Research & Development99.81M123.06M209.24M192.12M210.42M189.41M156.87M100.53M73.03M29.91M13.67M
R&D % of Revenue-584.77%208.08%197.93%157.48%91.46%743.53%473.76%263.87%800.83%3287.02%
Other Operating Expenses0-19.86M-207.03M-8.85M0-189.41M-156.87M-99.37M5.04M199K22K
Operating Income34.96M-145.81M-145M-151.74M-137.83M-37.36M-195.17M-114.4M-57.29M-32.68M-15.13M
Operating Margin %20.16%-692.83%-144.19%-156.33%-103.16%-18.04%-925.08%-539.16%-206.99%-874.94%-3637.5%
Operating Income Growth %--0.56%4.44%-10.09%-268.93%80.86%-70.6%-99.7%-75.31%-115.96%-
EBITDA39.26M-136.15M-136.16M-142.89M-129.36M-29.05M-187.91M-108.83M-56.27M-32M-14.93M
EBITDA Margin %22.63%-646.93%-135.4%-147.22%-96.82%-14.03%-890.65%-512.89%-203.31%-856.73%-3589.18%
EBITDA Growth %133.86%0.01%4.71%-10.46%-345.38%84.54%-72.66%-93.41%-75.85%-114.31%-
D&A (Non-Cash Add-back)4.3M9.66M8.84M8.85M8.47M8.31M7.26M5.57M1.02M680K201K
EBIT-82.89M-142.76M-118.92M-125.18M-130.06M-36.33M-195.17M-113.25M-57.29M-32.68M-15.13M
Net Interest Income00000000000
Interest Income00000000000
Interest Expense00000000000
Other Income/Expense6.81M3.05M26.08M26.56M7.78M1.03M4.95M9.02M5.04M199K22K
Pretax Income41.77M-142.76M-118.92M-125.18M-130.06M-36.33M-190.23M-105.39M-52.25M-32.48M-15.11M
Pretax Margin %24.08%-678.36%-118.26%-128.97%-97.33%-17.54%-901.64%-496.65%-188.78%-869.61%-3632.21%
Income Tax358K168K128K5.21M3.25M000000
Effective Tax Rate %0.86%-0.12%-0.11%-4.16%-2.5%0%0%0%0%0%0%
Net Income41.41M-142.93M-119.05M-130.39M-133.31M-36.33M-190.23M-105.39M-52.25M-32.48M-15.11M
Net Margin %23.87%-679.16%-118.39%-134.34%-99.77%-17.54%-901.64%-496.65%-188.78%-869.61%-3632.21%
Net Income Growth %138.44%-20.06%8.7%2.19%-266.95%80.9%-80.51%-101.7%-60.86%-114.96%-
Net Income (Continuing)41.41M-142.93M-119.05M-130.39M-133.31M-36.33M-190.23M-105.39M-52.25M-32.48M-15.11M
Discontinued Operations00000000000
Minority Interest00000000000
EPS (Diluted)0.37-1.39-1.23-1.56-1.62-0.45-2.45-1.62-0.76-0.63-1.78
EPS Growth %133.61%-13.01%21.15%3.7%-260%81.63%-51.23%-113.16%-20.63%64.61%-
EPS (Basic)--1.39-1.23-1.56-1.62-0.45-2.45-1.62-0.76-0.63-1.78
Diluted Shares Outstanding111.22M103M96.59M83.73M82.47M80.42M77.76M61.73M68.37M51.22M8.5M
Basic Shares Outstanding111.22M103M96.59M83.73M82.47M80.42M77.76M61.73M68.37M51.22M8.5M
Dividend Payout Ratio-----------

Key Metrics

Growth RegimeContracting
ProfitabilityWeak
Balance SheetAdequate
Cash FlowBurning
Top Statement Risk

Collapsed revenue base sustainability

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Revenue Base Collapses Toward Zero

Based on Alector's reported income statements, quarterly revenue has imploded from $54.2M in 2024Q4 to $3.3M in 2026Q2, with year-over-year declines of 57.8% to 88.5% across the last four quarters, suggesting collaboration-driven revenue has effectively vanished.

The trajectory is not a cyclical dip but an apparent structural loss of the revenue engine: the top line has fallen from roughly $15M per quarter in early 2024, spiked to $54.2M in 2024Q4, and then collapsed to single-digit millions. Growth rates of -76.9%, -78.8% and -88.5% across 2025 indicate the $54M quarter was almost certainly a one-time recognition event rather than a durable run-rate, so investors should not extrapolate any organic recovery absent a newly disclosed revenue source. The remaining $1-3M quarterly prints appear too small to materially fund the current operating cost structure.

Gross Margin Swings Signal Cost Distortions

According to ALEC's quarterly filings, gross margin swung from 85.6% in 2024Q1 to -99.2% in 2026Q1 as COGS of $33.6M dwarfed $3.7M of revenue, then snapped back to 100% in 2026Q2 when COGS printed zero, an unusual pattern warranting investigation of inventory or cost recognition.

A biotech with minimal product revenue should not be printing $27-46M quarterly COGS, which suggests these charges reflect inventory write-downs, manufacturing commitment losses or cost realignment tied to a discontinued program rather than true cost of goods. That interpretation matters because the apparent margin 'recovery' to 100% in 2026Q2 is an artifact of zero recorded COGS, not evidence of pricing power or operating efficiency. Until revenue rebuilds at scale, gross margin is analytically meaningless for ALEC and should be excluded from any peer comparison with commercial-stage names like ACAD at 91.7%.

2024Q4: A One-Quarter Earnings Mirage

As reported in ALEC's SEC filings, the fourth quarter of 2024 marks the clearest inflection: $54.2M of revenue compressed the operating loss to just -$7.2M and the net loss to -$2.1M, before revenue collapsed and losses re-widened to roughly -$24M per quarter thereafter.

The 2024Q4 print, with EPS of only -$0.02 versus -$0.34 to -$0.44 in surrounding quarters, would have supported a near-breakeven narrative had it persisted; its immediate reversal in 2025Q1 suggests the market's implied valuation at that time may have been anchored to an unsustainable revenue event. The lasting impact is that ALEC's baseline economics are now laid bare: roughly -$24M of quarterly operating loss on de minimis revenue. This inflection is the single most important period for modeling forward losses because it defines both the pre-collapse and post-collapse cost regimes.

Deep Retrenchment Cuts Burn by Half

Based on Alector's reported figures, quarterly R&D has fallen from $53.5M in 2024Q3 to $19.5M in 2026Q2 and SG&A from $15.8M to $8.3M, reductions of roughly 64% and 47% that have nonetheless failed to close the operating loss.

The scale and speed of the cuts imply pipeline prioritization, likely the discontinuation or out-licensing of programs that were consuming capital in 2024; R&D now constitutes about 59% of the combined R&D-plus-SG&A stack, still the dominant cost line and the primary lever management retains. However, the operating loss only narrowed from -$48.4M (2024Q3) to -$24.4M (2026Q2), meaning cost discipline has offset roughly half of the lost revenue rather than restored balance, so further reductions may be needed to extend runway. Investors should monitor whether SG&A stabilizes near $8M, which would suggest the remaining overhead approximates a true holding-company floor.

Shrinking SBC Improves Loss Quality

According to ALEC's reported filings, stock-based compensation has fallen from $10.3M in 2024Q1 to $2.6M in 2026Q2, a 75% reduction that materially improves the quality of the loss base, while net losses have consistently run smaller than operating losses, implying recurring non-operating income cushions the bottom line.

The declining SBC trajectory is a genuine positive for loss quality, as it indicates management is not papering over operating deterioration with equity issuance at prior run-rates; SBC represented over 25% of the operating loss in 2024 but only about 11% in 2026Q2. Separately, the persistent gap between operating and net losses (for example -$24.4M versus -$23.0M in 2026Q2) suggests interest income or other non-operating items are providing a modest, likely interest-rate-sensitive offset, which could compress if cash balances are drawn down. Because these non-operating components are not itemized in the supplied data, the durability of that cushion warrants further investigation in the full filings.

Cost Structure Outlasts Revenue Runway

As reported in recent SEC filings, despite cutting R&D by 64%, Alector still posted a -$24.4M operating loss in 2026Q2 on $3.3M of revenue, suggesting the cost structure remains anchored to a pipeline scale that current revenue no longer supports.

A short-seller would argue that the 2026Q2 'improvement' is largely cosmetic: the sequential narrowing from -$39.6M in 2025Q4 is driven by expensing discipline and the disappearance of large COGS charges, not by any recovering commercial franchise, leaving roughly $96M of annualized operating loss to be funded externally. Peer benchmarks sharpen the concern — ACAD converts a $1.1B revenue base into 9.8% operating margins, while ALEC's negative gross profit in six of ten quarters indicates no path to comparable economics without a new revenue catalyst. The key unresolved variable is balance sheet runway, which is not disclosed in the supplied income statement data; without visibility into cash and cash equivalents, the pace of future dilution or program divestiture cannot be reliably assessed.

ALEC — Frequently Asked Questions

Quick answers to the most common questions about buying ALEC stock.

What was Alector, Inc.'s (ALEC) revenue in 2025?

For fiscal year 2025, Alector, Inc. (ALEC) reported total revenue of $21.0M. This represents a 4958.9% increase compared to $0.4M in 2016.

Is Alector, Inc. (ALEC) profitable?

Alector, Inc. (ALEC) reported a net loss of $142.9M for the fiscal year ending 2025.

What is Alector, Inc.'s operating profit margin?

Alector, Inc. (ALEC) reported an operating income of $-145.8M, resulting in an operating profit margin of -692.8%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Alector, Inc.'s gross profit and gross margin?

Alector, Inc. (ALEC) generated $11.4M in gross profit for the year, representing a gross profit margin of 54.1%. This demonstrates the company's core pricing power and production efficiency.